Indeed, the experience of several randomized control trials has been included in the most recent guidelines ( In patients with T2DM, the treatment with SGLT2-i has been associated with a reduction in hospitalization for heart failure and cardiovascular deaths, regardless of pre-existing cardiovascular disease ( Several studies ( This heterogeneity in CV benefits across the trials, also among studies in which drugs of the same class have been used, could be explained by different study designs (i.e
TRANSCEND-T2D: Eli Lilly's parallel Phase 3 program evaluating retatrutide in type 2 diabetes
While Mounjaro or Ozempic can be powerful tools, they are most effective when paired with healthy lifestyle changes
PlexusDx sources all compounded medications from licensed 503A compounding pharmaciesthe gold standard for pharmaceutical preparation and sterility
Retatrutide is a promising experiment with a bigger mechanism and an unfinished evidence file
Ozempic (weekly injection, type 2 diabetes) Approved in 2017 at doses of 0.5 mg, 1 mg, and 2 mg weekly